Loading company…
Phialogics develops immune-modulating therapies for autoimmune diseases.
Founded in 2021, Phialogics develops therapies for autoimmune diseases using a platform designed to activate selected immune cell checkpoints and protect tissue from autoimmune attacks. The company is based in Switzerland and was founded by Andreas Ernst, Pascal Oromi, Michael J. Parnham, Andreas Weigert, and Andreas von Knethen. In April 2023, it raised EUR 0.06 million in pre-seed funding led by High-Tech Gründerfonds.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in